Prognostic value of allelic variants affecting the hemostatic system in the development of antiphospholipid syndrome and kidney lesion in patients with systemic lupus erythematosus


Cite item

Full Text

Abstract

AIM: To analyze the prognostic value of the polymorphisms of the thrombophilic genes: plasminogen activator inhibitor type 1 (PAI-1) (–675 4G/5G), factor XIII (FXIII) (G485T), fibrinogen (FBG) (G(–455)A), glycoprotein Ia (GPIa) (C807T), glycoprotein IIIa (GPIIIa) (T106C), and p22phox (C242T), as well as protein genes involved in the pathogenesis of endothelial dysfunction: subunits of p22phox NADH-oxidase (p22phox) (C242T), endothelial NO-synthase (eNOS) (G894T), and methylenetetrahydrofolate reductase (MTHFR) (С677Т) for the development of antiphospholipid syndrome (APS) and a type of progressive lupous nephritis (LN) in patients with systemic lupus erythematosus (SLE)/MATERIAL AND METHODS: One hundred patients with SLE were examined and, according to the presence of clinical and laboratory signs of APS were divided into 2 groups: 1) 50 SLE patients with APS; 2) 50 SLE patients without APS who were matched for gender and age with Group 1 patients. The gene polymorphisms were analyzed using standard molecular genetic techniques. The frequency of clinical manifestations of APS and the type of progressive nephritis were analyzed in view of the genotypes of the patients/RESULTS: Comparison of SLE patients with and without SLE revealed no statistically significant differences in the rates of alleles and genotypes. The patients with arterial and/or venous thrombosis in the presence of APS more frequently displayed a minor allele (T) and genotype (TT) of the p22phox gene than those with APS without thrombosis: T, 64.5 and 34%, respectively (p=0.033); TT, 36 and 7% (p=0.021); odds ratio (OR), 2.1 at 95% confidence interval (CI), 1.5 to 22.7). In the APS patients with livedo reticularis, the minor allele (T) and genotype (TT) of the eNOS gene were more common than in those without livedo: T, 33 and 10%, respectively (p=0.019); TT, 15 and 0% (p=0.031); OR, 2.49 at 95% CI, 1.2 to 28.9). In the patients with AFS and rapidly progressive LN (RPLN), the minor allele (T) and genotype (TT) of the MTHFR gene were much more frequently encountered: T, 46 and 27%, respectively (p=0.038); TT, 30 and 0% (p=0.033); OR, 3.1 at 95% CI, 1.4 to 32.7). The group of patients without APS exhibited no relationship between the examined polymorphisms and kidney lesion/CONCLUSION: The mutant allele of the p22phox gene increases the risk of arterial and venous thrombosis; the polymorphism of the eNOS gene may be related to the higher incidence of impaired blood microcirculation in SLE concurrent with APS. The risk of RPLN in SLE patients with APS is probably associated with MTHFR gene mutation.

About the authors

E N Borisov

ГБОУ ВПО "Первый МГМУ им. И.М. Сеченова" Минздрава России; МГУ им. М.В. Ломоносова

Email: borisov.fbm@gmail.com

T N Krasnova

ГБОУ ВПО "Первый МГМУ им. И.М. Сеченова" Минздрава России; МГУ им. М.В. Ломоносова

L M Samokhodskaia

МГУ им. М.В. Ломоносова

L V Ivanitskiĭ

ГБОУ ВПО "Первый МГМУ им. И.М. Сеченова" Минздрава России; МГУ им. М.В. Ломоносова

N V Nikiforova

ГБОУ ВПО "Первый МГМУ им. И.М. Сеченова" Минздрава России

N A Mukhin

ГБОУ ВПО "Первый МГМУ им. И.М. Сеченова" Минздрава России; МГУ им. М.В. Ломоносова

References

  1. Козловская Н.Л., Шилов Е.М., Метелева Н.А. и др. Клинические и морфологические особенности волчаночного нефрита при системной красной волчанке с антифосфолипидным синдромом. Тер арх 2006; 5: 21-31.
  2. Miyakis S., Lockshin M.D., Atsumi T. еt аl. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4 (2): 295-306.
  3. Moulis G., Delavigne K., Huguet F. еt аl. Antiphospholipid antibodies and the risk of thrombosis: A comparative survey between chronic immune thrombocytopenia and primary antiphospholipid syndrome. Rev Med Int 2011; 16 (10): 41-5
  4. Atsumi T., Bertolaccini M.L., Koike T. Genetics of antiphospholipid syndrome. Rheum Dis Clin North Am 2001; 27 (3): 565-572.
  5. Rodriguez-Garcia J.L., Bertolaccini M.L., Cuadrado M.J. et al. Clinical manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called ‘seronegative APS’). Ann Rheum Dis 2011; 105 (5): 431-439.
  6. Yonal I., Hindilerden F., Hancer V.S. et al. The impact of platelet membrane glycoprotein Ib alpha and Ia/IIa polymorphisms on the risk of thrombosis in the antiphospholipid syndrome. Thromb Res 2012; 129 (4): 486-491.
  7. Atochin D.N., Huang P.L. Endothelial nitric oxide synthase transgenic models of endothelial dysfunction. Pflugers Arch 2010; 460 (6): 965-974.
  8. Самоходская Л.М., Балацкий А.В., Садекова А.Н. и др. Определение индивидуального генетического риска развития сердечно-сосудистых заболеваний М: Изд-во Московского университета 2010.
  9. Ishii K., Murata M., Oguchi S. et al. Genetic risk factors for ischemic cerebrovascular disease - analysis on fifteen candidate prothrombotic gene polymorphisms in the Japanese population. Rinsho Byori 2004; 52 (1): 22-27.
  10. Zhou X.L., Yan S., Li Q. et al. A novel diagnostic measure of platelet-specific antibody in immune thrombocytopenia. Zhonghua Xue Ye Xue Za Zhi 2012; 33 (3): 200-203.
  11. Кириенко А.И., Леонтьев С.Г., Кожевникова Л.М. и др. Антифосфолипидный синдром в структуре гематогенной тромбофилии у пациентов с венозными тромбозами молодого и среднего возраста. Тер арх 2005; 5: 47-51.
  12. Cervera R., Tektonidou M.G., Espinosa G. et al. Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (II): thrombocytopenia and skin manifestations. Lupus 2011; 20 (2): 174-181.
  13. Ramesh S., Morelli C.N., Narango C. et al. Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosisin mice by antagonizing eNOS via Β2GPI and apoER2. J Clin Invest 2011; 121 (1): 120-125.
  14. Tincani A., Casu C., Cartella S. et al. Antiphospholipid antibody: laboratory, pathogenesis and clinical manifestations. Reumatismo 2010; 62 (1): 65-71.
  15. Козловская Н.Л., Боброва Л.А., Шкарупо В.В. и др. Клинико-морфологическая характеристика поражения почек у пациентов с генетической тромбофилией. Тер арх 2009; 81 (8): 30-36.
  16. Авдонин П.В, Кириенко А.И., Кожевникова Л.М. и др. Связь полиморфизма C677T в гене метилентетрагидрофолатредуктазы с высоким риском ТЭЛА у пациентов с венозными тромбозами из центрального региона России. Тер арх 2006; 6: 70-76.
  17. D’Amico M., Pasta L., Sammarco P. MTHFR C677TT, PAI1 4G-4G, V Leiden Q506, and prothrombin G20210A in hepatocellular carcinoma with and without portal vein thrombosis. J Thromb Thrombolys 2009; 28 (1): 73-78.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).